DrugPatentWatch Database Preview
Drugs in Development Information for Atrasentan
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Atrasentan?
Atrasentan is an investigational drug.
There have been 17 clinical trials for Atrasentan.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2006.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Kidney Diseases, and Diabetic Nephropathies. The leading clinical trial sponsors are Abbott, National Cancer Institute (NCI), and AbbVie (prior sponsor, Abbott).
Summary for Atrasentan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 56 |
| WIPO Patent Applications | 15 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2006-08-01) |
| Vendors | 22 |
Recent Clinical Trials for Atrasentan
| Title | Sponsor | Phase |
|---|---|---|
| Atrasentan Spermatogenesis and Testicular Function | AbbVie | Phase 2 |
| Study Of Diabetic Nephropathy With Atrasentan | AbbVie | Phase 3 |
| A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy | AbbVie (prior sponsor, Abbott) | Phase 2 |
Clinical Trial Summary for Atrasentan
Top disease conditions for Atrasentan
Top clinical trial sponsors for Atrasentan
US Patents for Atrasentan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
